Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
SPRING, Texas, July 08, 2024 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., presented today results from studies done in breast, lung,…
